PMID- 16195357
OWN - NLM
STAT- MEDLINE
DCOM- 20060127
LR  - 20200403
IS  - 0009-9147 (Print)
IS  - 1530-8561 (Electronic)
IS  - 0009-9147 (Linking)
VI  - 51
IP  - 12
DP  - 2005 Dec
TI  - Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other 
      chemokines predicts adverse outcome in severe acute respiratory syndrome.
PG  - 2333-40
AB  - BACKGROUND: Exaggerated activation of cytokines/chemokines has been proposed as a 
      factor in adverse outcome of severe acute respiratory syndrome (SARS). Previous 
      studies on chemokines have included only small numbers of patients, and the 
      utility of plasma chemokines as prognostic indicators is unclear. METHODS: We 
      studied 255 archival plasma samples collected during the first or second week 
      after disease onset. The chemokines interferon-inducible protein-10 (IP-10), 
      monokine induced by interferon-gamma (MIG), interleukin-8 (IL-8), monocyte 
      chemoattractant protein-1 (MCP-1), and regulated upon activation normal T cell 
      expressed and secreted (RANTES) were measured by cytometric bead array with a 
      4-color FACSCalibur flow cytometer. Reverse transcription and real-time 
      quantitative PCR and immunohistochemical staining were performed to analyze the 
      production of IP-10 in lung tissue at autopsy. Conditional logistic regression 
      was used to identify independent predictors for adverse disease outcome. RESULTS: 
      Increases in IP-10, MIG, and IL-8 during the first week after onset of fever were 
      associated with adverse outcome (intensive care unit admission or death) in the 
      univariate analysis. During the second week, only MIG concentration was 
      associated with prognosis. After adjusting for other risk factors, plasma IP-10 
      concentration at the first week remained as an independent prognostic factor, 
      with an odds ratio for adverse outcome of 1.52 (95% confidence interval, 
      1.05-2.55) per fold increase in plasma IP-10 concentration above the median. 
      During the second week, chemokines provided little independent prognostic 
      information. IP-10 was increased in lung tissue from patients who died of SARS. 
      CONCLUSIONS: Increased plasma IP-10 during the first week of SARS symptoms is an 
      independent predictor of outcome. Chemokine activation may be an early event in 
      SARS, and an exaggerated host response may produce complications.
FAU - Tang, Nelson Leung-Sang
AU  - Tang NL
AD  - Department of Chemical Pathology, Faculty of Medicine, The Chinese University of 
      Hong Kong, Shatin. nelsontang@cuhk.edu.hk
FAU - Chan, Paul Kay-Sheung
AU  - Chan PK
FAU - Wong, Chun-Kwok
AU  - Wong CK
FAU - To, Ka-Fai
AU  - To KF
FAU - Wu, Alan Ka-Lun
AU  - Wu AK
FAU - Sung, Ying-Man
AU  - Sung YM
FAU - Hui, David Shu-Cheong
AU  - Hui DS
FAU - Sung, Joseph Jao-Yiu
AU  - Sung JJ
FAU - Lam, Christopher Wai-Kei
AU  - Lam CW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20050929
PL  - England
TA  - Clin Chem
JT  - Clinical chemistry
JID - 9421549
RN  - 0 (Biomarkers)
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokines)
RN  - 0 (Chemokines, CXC)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers
MH  - Chemokine CXCL10
MH  - Chemokines/blood/*metabolism
MH  - Chemokines, CXC/blood/*metabolism
MH  - Female
MH  - Gene Expression Regulation
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Severe Acute Respiratory Syndrome/blood/*diagnosis/*metabolism/pathology
MH  - Time Factors
PMC - PMC7108146
EDAT- 2005/10/01 09:00
MHDA- 2006/01/28 09:00
PMCR- 2020/03/31
CRDT- 2005/10/01 09:00
PHST- 2005/10/01 09:00 [pubmed]
PHST- 2006/01/28 09:00 [medline]
PHST- 2005/10/01 09:00 [entrez]
PHST- 2020/03/31 00:00 [pmc-release]
AID - clinchem.2005.054460 [pii]
AID - 054460_clinchem2333 [pii]
AID - 10.1373/clinchem.2005.054460 [doi]
PST - ppublish
SO  - Clin Chem. 2005 Dec;51(12):2333-40. doi: 10.1373/clinchem.2005.054460. Epub 2005 
      Sep 29.